1FDA Approves First Bone Marrow Stimulator to Treat Immune-Related Low Platelet Counts[EB/OL]. FDA News, August 28, 2008. http://www.fda.gov/bbs/topies/NEWS/2008/NEW01876. html.
2Amgen, inc. HIGHLIGHTS OF PRESCRIBING INFORMATION: Nplate TM (romiplostim)[J/OL]. FDA News, August 22, 2008. http://www.fda.gov/cder/foi/label/2008/1252681bl.
3CINES D B, YASOTHAN U, KIRKPATRICK P. Romiplostiml[J]. NatRevDrugDiscov, 2008, 7(11):887-888.
4WANG B, NICHOL J L, SULLIVAN J T, et al. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand[J]. Clin Pharmacol Ther, 2004, 76(6):628-638.
5NICHOL J L. AMG 531: An investigational thrombopoiesisstimulating peptibody[J]. Pediatr Blood Cancer, 2006, 47(5 suppl): 723-725.
6KUTER D J, BUSSEL J B, LYONS R M, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind rattdomised controlled trial[J]. Lancet, 2008, 371(9610):395-403.
7JAWA V, HOKOM M, HU J, et al. Low immunogenicity to romiplostim in clinical studies with ITP subjects[J]. Blood (ASH Annual Meeting Abstracts), 2008,112(11):3425.
